An open-label pilot study of dose escalation of PEGASYS [peginterferon alfa-2a] on virological response in patients with chronic hepatitis C viral infection showing an early non-response to a standard course of PEGASYS plus ribavirin.

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Peginterferon alfa-2a (Primary) ; Ribavirin
Indications Hepatitis C
Focus Therapeutic Use
Acronyms PINGU
Sponsors Roche

Most Recent Events

06 Jun 2016 Study phase changed form phase 2 to phase 3
06 Jun 2016 Status changed from completed to discontinued.
23 Feb 2010 Status changed from active, no longer recruiting to completed as reported by Roche record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight